[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nsclc-non-small-cell-lung-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nsclc-non-small-cell-lung-carcinoma":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,54,85,113],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100583857","phase-3-study-of-daraxonrasib-rmc-6236-in-patients-with-ras-mutated-nsclc-rasolve-301-100583857",false,"NCT06881784","Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)","RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC","RASolve 301","Inclusion Criteria:\n\n* At least 18 years old and has provided informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Pathologically confirmed NSCLC, either locally advanced or metastatic, not amenable to curative surgery or radiotherapy.\n* Measurable disease per RECIST v1.1.\n* Adequate organ function (bone marrow, liver, kidney, coagulation).\n* One to two prior lines of therapy including an anti-PD-1\u002Fanti-PD(L)-1 agent and platinum-based chemotherapy.\n* Documented RAS mutation status, defined as Nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61).\n* Able to take oral medications.\n\nExclusion Criteria:\n\n* Prior therapy with direct RAS-targeted therapy or docetaxel.\n* Untreated central nervous system (CNS) metastases.\n* Medically significant comorbidities (significant cardiovascular disease, lung disease, or impaired GI function).\n* Ongoing anticancer therapy.\n* Pregnant or breastfeeding.","ALL","18 Years",{"count":20,"type":21},590,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.",[27,28,29,30,31],"NSCLC (Non-small Cell Lung Cancer)","Non-Small Cell Lung Cancer","NSCLC","NSCLC (Non-small Cell Lung Carcinoma)","NSCLC (Advanced Non-small Cell Lung Cancer)",[29,28,33,34,35,36,37,38,39,40],"Lung Cancer","RAS","KRAS","HRAS","NRAS","RAS Q61 Mutation","RAS G12 Mutation","RAS G13 Mutation","RECRUITING","2026-06-24",{"date":44,"type":45},"2026-06-25","ACTUAL",{"date":47,"type":45},"2025-05-06",{"date":49,"type":21},"2030-12-01",{"name":51,"class":52},"Revolution Medicines, Inc.","INDUSTRY",151,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":84},"100635340","phase-2-zorifertinib-plus-intra-ommaya-csf-chemotherapy-for-leptomeningeal-progression-in-nsclc-after-third-generation-egfr-tki-100635340","NCT07551414","Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI","A Prospective Study of Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI Therapy","Inclusion Criteria:\n\n* 1\\. Have fully understood the study and voluntarily signed the Informed Consent Form (ICF).\n\n  2\\. Subjects must be 18-75 years old before signing the Informed Consent Form (ICF).\n\n  3\\. During the screening phase, subjects must be diagnosed with non-small cell lung cancer (NSCLC) and test positive for EGFR-sensitive mutations (L858R and\u002For Exon 19Del).\n\n  4\\. Subjects who developed leptomeningeal progression after treatment with third-generation EGFR-TKIs and have no extracranial progression. The original third-generation EGFR-TKIs may be continued at the original dose or reduced dose.\n\n  5\\. Subjects diagnosed with leptomeningeal metastasis must have positive cerebrospinal fluid (CSF) cytology results. Subjects with negative CSF cytology but clinically diagnosed leptomeningeal metastasis based on symptoms, brain or spinal MRI imaging are also eligible for enrollment.\n\n  6\\. Subjects with both leptomeningeal progression and brain parenchymal progression are allowed to enroll.\n\n  7\\. Have undergone Ommaya reservoir implantation, with confirmation of no surgery-related complications and normal function of the Ommaya reservoir.\n\n  8\\. If accompanied by neurological symptoms, the following conditions must be met: able to take oral medication and swallow drugs; no need to increase hormone dosage to control central nervous system symptoms for at least 1 week prior to study treatment (i.e., symptom stability).\n\n  9\\. All anti-tumor therapy-related toxicities must have recovered to ≤ Grade 1 per CTCAE 5.0 criteria prior to starting study treatment (neurotoxicity related to platinum-based therapy may recover to ≤ Grade 2 per CTCAE 5.0 criteria); alopecia of any grade is allowed for enrollment.\n\n  10\\. Screening period test results must meet the following criteria:\n* Neutrophil count ≥ 1.5 × 10⁹\u002FL\n* Platelet count ≥ 100 × 10⁹\u002FL\n* Hemoglobin ≥ 90 g\u002FL\n* Serum creatinine ≤ 1.5 × ULN, or creatinine clearance (calculated via Cockcroft-Gault formula) ≥ 50 mL\u002Fmin\n* Total serum bilirubin ≤ 1.5 × ULN (≤ 3 × ULN allowed for patients with Gilbert syndrome or liver metastasis)\n* Aspartate aminotransferase (AST) ≤ 2.5 × ULN (≤ 5 × ULN allowed for patients with liver metastasis)\n* Alanine aminotransferase (ALT) ≤ 2.5 × ULN (≤ 5 × ULN allowed for patients with liver metastasis) 11. Estimated survival duration ≥ 3 months. 12. Karnofsky Performance Status (KPS) score ≥ 60.\n\nExclusion Criteria:\n\n* 1\\. Subjects with a history of cranial or spinal radiotherapy within 6 months prior to study drug administration are ineligible for enrollment. Radiotherapy for bone metastases within 3 months prior to study drug administration is also not permitted.\n\n  2\\. Subjects who have undergone major surgical procedures (e.g., intrathoracic, intra-abdominal, or pelvic surgery) within 4 weeks prior to the first dose of study treatment, or who have not yet recovered from side effects related to such surgeries, are ineligible for enrollment.\n\n  3\\. Subjects with any other currently active malignant tumor besides NSCLC are excluded.\n\n  4\\. Subjects with clinically significant, uncontrolled cardiac disease and\u002For cardiac events occurring within the past 6 months, such as:\n  1. Myocardial infarction within 6 months prior to screening;\n  2. Documented history of heart failure (NYHA Class III-IV);\n  3. Uncontrolled hypertension: systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg, regardless of antihypertensive medication use (adjustment of antihypertensive drugs prior to screening is permitted);\n  4. Drug-refractory arrhythmias;\n  5. Screening QTcF \\>470 ms;\n  6. Left ventricular ejection fraction (LVEF) \\\u003C50%. 5. Subjects with gastrointestinal diseases or severe impairment of gastrointestinal function that may significantly affect drug absorption (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome).\n\n  6\\. Subjects unable to discontinue the following medications within 1 week prior to study drug administration and during the study period:\n  1. Strong inducers or strong inhibitors of CYP3A4;\n  2. Drugs that may prolong the QT interval or induce torsades de pointes. 7. Subjects with prior or current HIV infection are excluded. HCV antibody-positive subjects may be enrolled if HCV RNA is undetectable (with the lower limit of detection defined per each center's standards) and there is no concurrent hepatitis B virus (HBV) infection. HBV-infected subjects may be enrolled if they meet the following conditions:\n\n  \u003C!-- -->\n\n  1. For active hepatitis B patients: at least 6 weeks of antiviral therapy prior to starting study treatment, with HBV DNA \\\u003C100 IU\u002FmL and ALT\u002FAST levels \\\u003CULN;\n  2. For resolved or chronic hepatitis B patients: at least 2 weeks of prophylactic antiviral therapy prior to starting study treatment, with HBV DNA below 100 IU\u002FmL (e.g., inactive carriers) and ALT\u002FAST levels \\\u003CULN.\n\n  8\\. Pregnant or breastfeeding women; women of childbearing potential must agree to use highly effective contraception during the treatment period and for 3 months after the last dose; fertile men must also use highly effective contraception during the treatment period and for 6 months after the last dose.\n\n  9\\. Subjects with a prior history of interstitial lung disease, including clinically significant radiation pneumonitis (e.g., affecting daily life or requiring therapeutic intervention).\n\n  10\\. Subjects who have previously received zorifertinib or its active pharmaceutical ingredient.\n\n  11\\. Known hypersensitivity to zorifertinib's active ingredients, excipients, or drugs with similar chemical structures or classes.\n\n  12\\. Subjects with other comorbid diseases or factors that, in the investigator's judgment, would pose excessive risk to the subject upon participation in the clinical trial.","75 Years",{"count":63,"type":21},38,[65],"PHASE2","A Prospective Study of Zorifertinib Combined with Intra-Ommaya Reservoir Cerebrospinal Fluid Chemotherapy for Leptomeningeal Progression in NSCLC Patients After Third-Generation EGFR-TKI Therapy",[30,68,69,70],"Leptomeningeal Metastasis","EGFR-TKI Sensitizing Mutation","Zorifertinib",[68,29,72,69],"zorifertinib","NOT_YET_RECRUITING","2026-04-22",{"date":76,"type":45},"2026-04-24",{"date":78,"type":21},"2026-05-30",{"date":80,"type":21},"2028-05-30",{"name":82,"class":83},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",1,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":61,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":95,"conditions":96,"keywords":99,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":84},"100617099","phase-2-firmonertinib-combined-with-definitive-radiotherapy-in-stage-iii-unresectable-egfr-uncommon-mutant-pulmonary-adenocarcinoma-100617099","NCT07314216","Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma","A Single-Arm, Multicenter, Phase II Clinical Trial of Firmonertinib in Combination With Definitive Radiotherapy for Patients With Stage III Unresectable Pulmonary Adenocarcinoma Harboring Positive EGFR Uncommon Driver Mutations","Inclusion Criteria:\n\n1. Provision of informed consent prior to any study-specific procedures;\n2. Age 18-75 years;\n3. ECOG performance status of 0 or 1 with no deterioration within the 2 weeks prior to enrollment, and a life expectancy of ≥12 weeks;\n4. Histologically or cytologically confirmed non-squamous non-small cell lung cancer;\n5. Assessed as having unresectable or inoperable locally advanced non-squamous non-small cell lung cancer suitable for definitive radiotherapy (Stage III according to AJCC 9th edition TNM staging);\n6. Presence of EGFR uncommon mutations (excluding 19del, L858R, T790M) confirmed by genetic testing in a tertiary grade A hospital; specific types are detailed in Appendix 11;\n7. No prior systemic anti-tumor therapy or radiotherapy for locally advanced non-small cell lung cancer before the first dose of the study drug, including chemotherapy, biologic therapy, targeted therapy, immunotherapy, or investigational drug therapy;\n8. At least one accurately measurable lesion according to RECIST 1.1, which has not been previously irradiated and was not biopsied during the screening period. If a subject has only one measurable lesion, biopsy of that lesion is permitted, provided the baseline imaging is performed at least 14 days after the biopsy;\n9. Female subjects must use highly effective contraception (see restrictions) for at least 2 weeks prior to the first dose, have a negative pregnancy test, must not be breastfeeding at the time of treatment initiation, OR must meet at least one of the following criteria at screening to demonstrate the absence of childbearing potential;\n\n   * Postmenopausal, defined as age over 50 years and amenorrhea for at least 12 months after cessation of all exogenous hormonal treatments;\n   * For women aged 50 years or younger, amenorrhea for 12 months or more after cessation of exogenous hormone therapy and luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels within the institutional postmenopausal range;\n   * Irreversible surgical sterilization documented by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy, but excluding tubal ligation;\n10. Male subjects must be willing to use barrier contraception ;\n11. Ability to comply with the study protocol and follow-up procedures, and capable of oral medication intake\n\nExclusion Criteria:\n\n1. Pathological type is pulmonary squamous cell carcinoma or small cell lung cancer;\n2. Known history of hypersensitivity to the active or inactive excipients of firmonertinib, or to drugs with a similar chemical structure or class to the investigational drug;\n3. Confirmed presence of EGFR exon 19 deletion or exon 21 L858R mutation;\n4. Presence of metastatic disease, or assessed as unsuitable for definitive radiotherapy; or unable to undergo definitive radiotherapy due to extensive tumor volume resulting in normal tissue radiation doses exceeding dose constraints;\n5. NSCLC involving the superior sulcus, large cell neuroendocrine carcinoma (LCNEC), or sarcomatoid tumor;\n6. Prior to the first dose of the study drug, patients who have received any of the following treatments;\n\n   * Any prior EGFR-TKI therapy;\n   * Patients who have received intrapleural infusion therapy; these patients may be enrolled only after pleural effusion has been stable for 28 days or more;\n   * Major surgery within 28 days prior to the first dose of study drug (In China, major surgery is defined according to the Level 3 and Level 4 surgeries specified in the \"Administrative Measures for the Clinical Application of Medical Technologies\" implemented on May 1, 2009; see Appendix 5 for details);\n   * Treatment with strong CYP3A4 inhibitors or inducers within 7 days prior to the first dose, or patients who require continued use of these drugs during the study period (see Appendix 6 for drug list);\n   * Treatment with traditional Chinese medicine or Chinese patent medicine for anti-tumor indications within 7 days prior to the first dose, or patients who require continued use of these drugs during the study period;\n   * Concurrent use of medications known to prolong the QTc interval or that may induce Torsade de Pointes, and which require continued administration during the study period (see Appendix 8 for drug list);\n   * Discontinuation of other investigational drugs within less than 5 half-lives or 2 months (whichever is longer) prior to the first dose;\n7. Toxicities from prior anti-tumor therapy have not recovered to ≤ CTCAE Grade 1 prior to the first dose of the study drug (except for alopecia or chemotherapy-induced peripheral neuropathy ≤ CTCAE Grade 2);\n8. Patients with unstable pleural effusion;\n9. History of, or diagnosis with, another malignancy within the past 5 years, except for effectively controlled basal cell carcinoma of the skin, carcinoma in situ of the cervix, and ductal carcinoma in situ of the breast;\n10. Recent active digestive tract diseases, such as duodenal ulcer, ulcerative colitis, ileitis, etc.; intestinal perforation; intestinal fistula; or other conditions deemed by the investigator as potentially leading to gastrointestinal bleeding or perforation; or refractory nausea\u002Fvomiting, chronic gastrointestinal diseases, inability to swallow the study drug, or prior extensive bowel resection that would preclude adequate absorption of firmonertinib;\n11. Evidence of any severe or uncontrolled systemic disease, including uncontrolled hypertension, diabetes, active bleeding, etc., which in the investigator's judgment is not conducive to the patient's participation in the study or may compromise protocol compliance; or active infection including Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus (HIV) (including any patient receiving intravenous treatment for infection; active hepatitis B infection at a minimum includes all patients serologically positive for HBsAg with HBV DNA \\>1000 copies\u002FmL);\n12. History of interstitial lung disease (ILD), drug-induced ILD, prior history of radiation pneumonitis requiring steroid treatment, or any evidence of active ILD;\n13. Any known evidence of corneal lesions\u002Fdamage;\n14. Inadequate bone marrow reserve or organ function based on examinations within 28 days prior to the first dose of study drug (without transfusion or blood products, granulocyte colony-stimulating factor, or other hematopoietic stimulators within 2 weeks prior to testing);\n\n    * Absolute neutrophil count \\\u003C1.5 × 10\\^9\u002FL; Platelet count \\\u003C100 × 10\\^9\u002FL; Hemoglobin \\\u003C90 g\u002FL;\n    * Alanine aminotransferase \\> 2.5 × ULN; Aspartate aminotransferase \\>2.5 × ULN; Total bilirubin \\> 1.5 × ULN, or for patients with liver metastases, AST and\u002For ALT \\>5 × ULN;\n    * Serum creatinine \\>1.5 × ULN, OR Creatinine clearance \\\u003C50 mL\u002Fmin (measured or calculated using the Cockcroft and Gault formula, see Appendix 2);\n    * International Normalized Ratio \\> 1.5, AND Activated Partial Thromboplastin Time \\>1.5 × ULN;\n15. Any of the following cardiac criteria;\n\n    * Mean resting corrected QT interval (QTc) \\>470 msec obtained from 3 consecutive ECGs, calculated using Fridericia's formula;\n    * Any clinically significant abnormalities in rhythm, conduction, or morphology of resting ECG within 28 days prior to the first dose, e.g., complete left bundle branch block, third-degree, and second-degree heart block;\n    * Cardiac function assessment within 28 days prior to the first dose: Left Ventricular Ejection Fraction \\\u003C50%; history of myocardial infarction, severe\u002Funstable angina, or coronary artery bypass graft surgery within the past 6 months; or cardiac insufficiency ≥ NYHA Class 2;\n16. Pregnancy or lactation;\n17. Patients judged by the investigator as ineligible for the study, such as those unlikely to comply with the study protocol, procedures, and requirements; or any other circumstances warranting exclusion based on the investigator's discretion",{"count":93,"type":21},15,[65],"This is a prospective, single-arm, Phase II clinical study aimed at evaluating the efficacy and safety of 160mg fimonertinib in combination with definitive radiotherapy for patients with EGFR uncommon driver mutation-positive, Stage III unresectable lung adenocarcinoma. The primary endpoint is Progression-Free Survival (PFS), assessed by the investigator according to RECIST 1.1 criteria, defined as the time from the first dose to objective disease progression or death (from any cause). Secondary endpoints include PFS by different mutation types, OS, ORR, DCR, as well as adverse events and their severity.",[30,97,98],"Stage III","EGFR Uncommon Mutations",[100,101,102,103],"unresectable Stage III lung adenocarcinoma","EGFR uncommon mutations","Firmonertinib","radiotherapy","2026-01-03",{"date":106,"type":45},"2026-01-06",{"date":108,"type":21},"2026-01-01",{"date":110,"type":21},"2030-12-31",{"name":112,"class":83},"Hunan Cancer Hospital",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":134,"locationsCount":84},"100596789","phase-3-low-dose-nivolumab-with-chemotherapy-vs-standard-chemotherapy-as-first-line-treatment-in-advanced-or-metastatic-nsclc-100596789","NCT07050043","Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC","A Phase III RCT Comparing Low Dose Immunotherapy (Nivolumab) Combined With Standard Chemotherapy vs Standard Chemotherapy as First-line Treatment in Patients With Locally Advanced or Metastatic NSCLC","LEDANG","Inclusion Criteria:\n\n1. Male\u002Ffemale participants who are at least 18 years of age on the day of signing informed consent.\n2. Histologically confirmed, treatment naïve, locally advanced, or metastatic (stage IIIB - IV (per AJCC version 8), squamous or non-squamous NSCLC with documented PD-L1 expression and is not eligible for definitive chemo-radiation curative therapy and surgery.\n3. Patients must be treatment naïve with respect to locally advanced or metastatic disease. Patients who received prior treatment with curative intent for early stage disease and develop recurrent advanced\u002F metastatic disease must have completed treatment at least 6 months prior to first dose of IP.\n4. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Evaluation of ECOG is to be performed within 7 days prior to the first dose of study intervention.\n5. At least 1 measurable lesion by RECIST 1.1 in solid tumors criteria.\n6. Participants must have adequate organ function including the following laboratory values at the screening visit as per Table 2:\n7. If a participant has brain or meningeal metastases, the participant must meet the following criteria:\n\n   1. Metastatic brain lesions do not require immediate intervention. Note: Asymptomatic, treated and stable as well as not requiring steroids for at least 2 weeks prior to start study Treatment.\n   2. Carcinomatous meningitis is excluded regardless of clinical stability.\n8. A male participant must agree to use a contraception starting with the first dose of study treatment through the treatment period and for at least 90 days after the last dose of study treatment and refrain from donating sperm during this period.\n9. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:\n\n   1. Not a woman of childbearing potential (WOCBP), OR,\n   2. A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 180 days after the last dose of study treatment.\n10. Can provide evaluable archival tumor tissue sample or willing to provide tissue from newly obtained core or excisional biopsy or fine needle aspirate (FNA) cell block form of tumor lesion not previously irradiated. Note: Formalin fixed, paraffin embedded (FFPE) tissue blocks or slides allowed.\n\nExclusion Criteria:\n\n1. Presence of EGFR, ALK , ROS1 mutation(s).\n2. Patients with locally advanced disease who can receive other potentially curative therapies, such as patients who can afford to pay for or can otherwise access clinically approved doses of immunotherapy.\n3. Prior treatment with any anti-PD-1, anti-PD-L1 or any other antibody targeting an immune checkpoint.\n4. Use of any live vaccines against infectious diseases within 28 days of first dose of IP(s).\n5. Underlying medical conditions that, in the Investigator's or Sponsor PI's opinion, will make the administration of IP(s) hazardous, including but not limited to interstitial lung disease, including history of interstitial lung disease or non-infectious pneumonitis (lymphangitic spread of NSCLC is not disqualifying), or active viral, bacterial, or fungal infections requiring parenteral treatment within 14 days of the initiation of the IP.\n6. Concurrent medical condition requiring the use of supra-physiologic doses of corticosteroids (\\> 10 mg\u002Fday of oral prednisone or equivalent) or immunosuppressive medications (absorbable topical corticosteroids are not excluded).\n7. Active hepatitis B and C infection or human immunodeficiency virus antibody (HIV-1 and\u002For HIV-2) positive at screening.\n8. Known hypersensitivity to recombinant proteins, or any excipient contained in the IP formulations.\n9. Known history of autoimmune disease currently on immunosuppressive medications.\n10. Known history of second malignancy within two years prior enrolment.\n11. Prognosis of three months or less.\n12. A WOCBP who has a positive urine pregnancy test within 72 hours prior to treatment allocation. If the urine test positive or cannot be confirmed as negative, a serum pregnancy test will be required.",{"count":122,"type":21},123,[24],"This is a multicenter, two-arm randomized, parallel group design trial to evaluate superiority and safety of low dose Nivolumab (40mg) combined with standard chemotherapy versus standard chemotherapy alone in patients with non-small cell lung cancer.",[30,126,127],"First Line Therapy","Locally Advanced\u002FMetastatic NSCLC","2025-06-25",{"date":130,"type":45},"2025-07-03",{"date":132,"type":45},"2025-05-19",{"date":110,"type":21},{"name":135,"class":136},"Dr Arvindran A\u002FL Alaga","OTHER_GOV"]